A patent protecting sitagliptin from generic competition prevents any generic Juvisync (sitagliptin/simvastatin) products from being manufactured. The earliest predictable date that a generic version might become available is in April 2017, when this patent expires. Although you can take the two active ingredients in Juvisync separately, it is typically less expensive to take Juvisync.
In September 2013, Merck & Co, Inc., announced that it would be discontinuing this medication. It is clear that this decision was made for business reasons, not for safety reasons.
Can I Buy Generic Juvisync?Juvisync® (sitagliptin/simvastatin) is a prescription medication. It contains two different active ingredients: simvastatin (Zocor®) and sitagliptin (Januvia®). Simvastatin is a cholesterol medication, and sitagliptin is a diabetes medication.
Juvisync is manufactured by MSD International GmbH for Merck & Co., Inc. It is currently under the protection of a patent that prevents any generic Juvisync from being manufactured in the United States.
When Will a Generic Version Be Available?The simvastatin component of Juvisync is not protected by any patents (all the applicable patents have already expired, and simvastatin is available in generic form). However, the sitagliptin component has several unexpired patents, the first of which is set to expire in April 2017. This is the earliest predictable date that a generic version of Juvisync could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for new Juvisync uses. Once the drug goes off-patent, there may be several companies that manufacture a generic Juvisync drug.